Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis

Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis

Abstract Background Evaluation of costs and short-term cost-effectiveness of infliximab plus methotrexate (IFX + MTX); triple therapy of hydroxychloquine, sulphasalazine, and methotrexate (TRIPLE); or methotrexate monotherapy (MTX) in patients with new-onset polyarticular juvenile idiopathic arthrit...

Full description

Bibliographic Details
Main Authors: Maarit Tarkiainen, Pirjo Tynjälä, Paula Vähäsalo, Kristiina Aalto, Liisa Kröger, Katariina Rebane, Pekka Lahdenne, Janne Martikainen
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Juvenile idiopathic arthritis
Biological therapy
Disease-modifying anti-rheumatic drugs; health economic evaluation
Online Access:https://doi.org/10.1186/s12969-022-00748-w

Internet

https://doi.org/10.1186/s12969-022-00748-w

Similar Items